Back to search results

Long-Term Follow-Up for TScan TCR-T Products

This is an observational study to follow people who have previously received TSC-100 or TSC-101, which are special cell therapies (TCR-T products) designed to fight cancer. The study will monitor your health for 15 years after you received the cell therapy to see how safe and effective it is in the long run. This study is for people aged 18 to 110 who have already participated in a TScan Therapeutics clinical study where they received one of these TCR-T therapies. The main goal is to track any side effects that might happen over a long period. This study is currently enrolling participants.

Study design
This is an observational study planning to enroll 1000 participants. It is designed to follow people over time without giving them new study drugs.
What's involved
You will be monitored for safety and effectiveness over a 15-year period after completing a previous TSCAN-001 interventional trial.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for 15 years after receiving the TCR-T cell therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06976736

A Long Term Follow-up Study of TScan TCR-T Products

Recruiting
Not specifiedAges 18+Observational
TScan Therapeutics, Inc.
~1,000 participants
Updated 2025-09-10 on ClinicalTrials.gov
What's tested:Observational

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Measured over 15 years post TCR-T administration

Conditions

AML
ALL
MDS

Explore related trials

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome

Where it's being run

2 sites across 2 states
California1
New York1

Study leadership

  • Michelle Matzko, MD · STUDY_DIRECTOR · Medical Monitor

Who to contact

Madhavi Desai
[email protected]
(857) 399-9832
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics.
Signed informed consent.

Exclusion

None

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)15 years post TCR-T administration

    To assess the long-term safety of TSC-100 and TSC-101 in participants by evaluating the incidence, duration, and outcome of adverse events and adverse events of special interest.